Cargando…

血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究

BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) have the highest incidence of lung cancer which treatment principles are diagnosis and treatment as early as possible. Because of its insidious onset and lack of specific markers for early screening, most patients are at an advanced stage...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348161/
https://www.ncbi.nlm.nih.gov/pubmed/30674389
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.05
_version_ 1783390042402586624
collection PubMed
description BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) have the highest incidence of lung cancer which treatment principles are diagnosis and treatment as early as possible. Because of its insidious onset and lack of specific markers for early screening, most patients are at an advanced stage when diagnosed which results in a low 5-year survival rate and poor prognosis. Therefore Exploring a sensitive biomarker is the focus of current diagnosis and treatment of lung cancer. The aim of this study is to investigate the biological markers in serum of patients with Ⅰ-Ⅱb stage NSCLC by differential peptidomics analysis. METHODS: The serum peptidome was compared and analyzed among the groups of normal health controls, benign lung diseases and early stage NSCLC patients using a nano ultra-performance liquid chromatography combined with a quadrupole-orbitrap mass spectrometer. The differentially expressed polypeptides were identified and analyzed quantitatively to screen the tumor biomarkers for the early diagnosis of NSCLC patients. RESULTS: According to the Swiss-Prot database, a total of 545 polypeptides originated from 118 proteins were identified. The spectral numbers of serum polypeptides in each group were compared and a total of 201 polypeptides differentially expressed were found. Following a quantitative analysis of the above peptides, we found that there were 7 peptides with the coefficient of variation (CV) less than 30% and among them the peptide of QGAKIPKPEASFSPR from ITIH4 was down-regulated and the peptide of CDDYRLC from MGP was up-regulated in NSCLC group. CONCLUSION: The tumor biomarkers obtained by serum peptidome technology can provide a new clue for early diagnosis of NSCLC and the specific peptides hydrolyzed from ITIH4 and MGP may be the serum biological markers for early NSCLC patients.
format Online
Article
Text
id pubmed-6348161
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-63481612019-02-11 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) have the highest incidence of lung cancer which treatment principles are diagnosis and treatment as early as possible. Because of its insidious onset and lack of specific markers for early screening, most patients are at an advanced stage when diagnosed which results in a low 5-year survival rate and poor prognosis. Therefore Exploring a sensitive biomarker is the focus of current diagnosis and treatment of lung cancer. The aim of this study is to investigate the biological markers in serum of patients with Ⅰ-Ⅱb stage NSCLC by differential peptidomics analysis. METHODS: The serum peptidome was compared and analyzed among the groups of normal health controls, benign lung diseases and early stage NSCLC patients using a nano ultra-performance liquid chromatography combined with a quadrupole-orbitrap mass spectrometer. The differentially expressed polypeptides were identified and analyzed quantitatively to screen the tumor biomarkers for the early diagnosis of NSCLC patients. RESULTS: According to the Swiss-Prot database, a total of 545 polypeptides originated from 118 proteins were identified. The spectral numbers of serum polypeptides in each group were compared and a total of 201 polypeptides differentially expressed were found. Following a quantitative analysis of the above peptides, we found that there were 7 peptides with the coefficient of variation (CV) less than 30% and among them the peptide of QGAKIPKPEASFSPR from ITIH4 was down-regulated and the peptide of CDDYRLC from MGP was up-regulated in NSCLC group. CONCLUSION: The tumor biomarkers obtained by serum peptidome technology can provide a new clue for early diagnosis of NSCLC and the specific peptides hydrolyzed from ITIH4 and MGP may be the serum biological markers for early NSCLC patients. 中国肺癌杂志编辑部 2019-01-20 /pmc/articles/PMC6348161/ /pubmed/30674389 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.05 Text en 版权所有©《中国肺癌杂志》编辑部2019 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title_full 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title_fullStr 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title_full_unstemmed 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title_short 血清多肽组学作为Ⅰ期-Ⅱb期非小细胞肺癌标志物的初步研究
title_sort 血清多肽组学作为ⅰ期-ⅱb期非小细胞肺癌标志物的初步研究
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348161/
https://www.ncbi.nlm.nih.gov/pubmed/30674389
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.05
work_keys_str_mv AT xuèqīngduōtàizǔxuézuòwèiiqīiibqīfēixiǎoxìbāofèiáibiāozhìwùdechūbùyánjiū
AT xuèqīngduōtàizǔxuézuòwèiiqīiibqīfēixiǎoxìbāofèiáibiāozhìwùdechūbùyánjiū
AT xuèqīngduōtàizǔxuézuòwèiiqīiibqīfēixiǎoxìbāofèiáibiāozhìwùdechūbùyánjiū
AT xuèqīngduōtàizǔxuézuòwèiiqīiibqīfēixiǎoxìbāofèiáibiāozhìwùdechūbùyánjiū
AT xuèqīngduōtàizǔxuézuòwèiiqīiibqīfēixiǎoxìbāofèiáibiāozhìwùdechūbùyánjiū